Cy5.5 NHS Ester (Non-Sulfonated): Transforming Near-Infrared Biomolecule Labeling and In Vivo Imaging

Principle and Setup: The Power of Near-Infrared Fluorescence for Biomolecule Labeling

Advances in molecular imaging hinge on reagents that combine high sensitivity, spectral specificity, and robust bioconjugation chemistry. Cy5.5 NHS ester (non-sulfonated) exemplifies this next-generation class of near-infrared fluorescent dyes for biomolecule labeling. Its N-hydroxysuccinimide (NHS) ester group reacts rapidly and selectively with primary amines on proteins, peptides, and oligonucleotides, forming stable amide bonds that withstand rigorous downstream processing. Cy5.5 NHS ester stands out with its excitation and emission maxima at 684 nm and 710 nm, respectively, enabling deep-tissue fluorescence imaging with reduced autofluorescence and improved signal-to-noise ratios compared to visible-spectrum dyes.

Key data-driven features include:

• Excitation/Emission (Cy5.5): 684/710 nm
• Solubility: ≥35.82 mg/mL in DMSO
• Stability: 24 months at -20°C (solid, dark)
• Labeling Chemistry: Efficient, one-step NHS ester–amine conjugation
• Applications: Fluorescent dye for protein conjugation, optical imaging of tumors, in vivo fluorescence imaging, and molecular diagnostics

Given the increasing evidence for microbiome involvement in tumor progression—and the growing need for precise, noninvasive imaging tools—Cy5.5 NHS ester offers a versatile solution for both fundamental research and translational applications. Its use as a tumor imaging agent and amino group labeling reagent is thoroughly documented in the literature and product reviews (see review).

Optimized Workflow: Stepwise Protocol for Cy5.5 NHS Ester Biomolecule Labeling

1. Reagent Preparation

• Storage: Keep Cy5.5 NHS ester (non-sulfonated) solid at -20°C, protected from light. Avoid repeated freeze-thaw cycles.
• Dissolution: Immediately before use, dissolve in anhydrous DMSO or DMF to a concentration of 10–20 mM. Do not store in solution.

2. Target Biomolecule Preparation

• Buffer: Equilibrate proteins or oligonucleotides in amine-free buffer (e.g., 0.1 M sodium bicarbonate, pH 8.3). Avoid Tris or glycine buffers, as they compete for NHS reactivity.
• Concentration: Typical protein concentrations range from 1–10 mg/mL; oligonucleotides, 50–200 µM.

3. Labeling Reaction

1. Add Cy5.5 NHS ester solution to the biomolecule in a 3–10× molar excess, depending on desired labeling density.
2. Incubate at room temperature (20–25°C) for 1 hour, protected from light. Gently mix to ensure uniform conjugation.

Example: Labeling 1 mg of IgG (approx. 6.7 nmol) with 67 nmol dye (10× molar excess) in 100 µL reaction volume.

4. Quenching and Purification

1. Quench unreacted NHS ester by adding 10 mM Tris-HCl (pH 7.5) or 100 mM glycine, incubate 10 minutes.
2. Remove free dye via gel filtration (e.g., Sephadex G-25), dialysis, or ultrafiltration (10 kDa MWCO).

5. Quality Assessment

• Determine degree of labeling (DOL) by absorbance at 684 nm (dye) and 280 nm (protein), applying correction factors.
• Confirm functional activity where applicable—e.g., antigen binding for antibodies, integrity for labeled oligos.

Advanced Applications: Cy5.5 NHS Ester in Tumor Imaging and Beyond

Cy5.5 NHS ester’s spectral and chemical attributes empower advanced in vivo fluorescence imaging workflows, especially in cancer research, microbiome studies, and drug development. The dye’s near-infrared emission penetrates tissues more deeply and with less background than visible-spectrum fluorophores, enabling:

• Optical Imaging of Tumors: Labeled antibodies, peptides, or nanoparticles can delineate tumor margins and track metastases in live animal models. In a recent Science Advances study, optical imaging using near-infrared dyes enabled real-time visualization of tumor-associated bacterial burden and vaccine efficacy in metastatic breast cancer models, demonstrating clear tumor localization and pharmacokinetic advantages.
• Microbiome-Targeted Imaging: By labeling anti-bacterial antibodies or engineered nanovaccines with Cy5.5, researchers can selectively image and quantify bacteria within tumor tissues, as highlighted in research leveraging polyvalent vaccines to modulate the intratumoral microbiome (see complementary discussion).
• Molecular Diagnostics: Cy5.5-labeled oligonucleotide probes enable multiplexed nucleic acid detection with minimal autofluorescent interference, critical in high-sensitivity diagnostic panels.

Compared to other fluorescent dyes, Cy5.5 NHS ester offers a unique combination of low background fluorescence, strong tissue penetration, and robust conjugation efficiency. These features are especially advantageous for in vivo fluorescence imaging and near-infrared fluorescence imaging in preclinical and translational settings.

Troubleshooting and Optimization: Maximizing Cy5.5 NHS Ester Performance

Common Pitfalls and Solutions

• Low Labeling Efficiency: Ensure protein or oligo is in an amine-free buffer; use freshly prepared dye solution; optimize dye-to-protein ratio.
• Precipitation or Aggregation: Avoid excessive dye addition (>10× molar excess) and use gentle mixing. For proteins with multiple exposed amines, titrate dye addition to minimize structural perturbation.
• High Background Signal: Purify conjugated product thoroughly to remove unreacted dye. For in vivo studies, validate clearance and biodistribution profiles.
• Dye Degradation: Protect dye and conjugates from prolonged light exposure; always store as a solid at -20°C.

Protocol Enhancements

• Use microspin desalting columns for rapid, efficient removal of free dye.
• Apply degree-of-labeling calculations to standardize between batches and ensure reproducibility.
• Optimize reaction pH (8.0–8.5) for maximal NHS ester reactivity without compromising biomolecule integrity.
• Validate specificity in complex biological samples using appropriate negative controls.

Cross-Referencing Techniques

For more detailed protocol guidance and comparative dye performance, this comprehensive overview complements the present workflow by outlining key considerations in protein and nucleic acid labeling, including buffer selection and analytical readouts.

Future Outlook: Expanding the Toolkit for Molecular Imaging and Therapeutics

The intersection of near-infrared fluorescent labeling and next-generation cancer therapies continues to advance rapidly. As demonstrated by Kang et al. (2025 Science Advances), precise imaging of tumor-associated bacteria and immune responses is essential for evaluating novel interventions such as polyvalent nanovaccines. Cy5.5 NHS ester (non-sulfonated) is ideally positioned to play a central role in these efforts, offering reliable, high-contrast labeling for both preclinical research and translational studies.

Looking ahead, anticipated developments include:

• Integration with multiplexed imaging platforms for simultaneous tracking of multiple targets in vivo.
• Enhanced pharmacokinetic profiling of labeled therapeutics and diagnostics.
• Wider adoption in microbiome-focused cancer research, leveraging the synergy between optical imaging and targeted immunotherapies.

For researchers seeking robust, reproducible, and high-sensitivity labeling, Cy5.5 NHS ester (non-sulfonated) remains a go-to fluorescent dye for protein conjugation and advanced molecular imaging workflows. Its proven performance, as underscored in recent literature and practical reviews, continues to drive innovation at the interface of molecular biology, oncology, and bioengineering.